Theramex
https://www.theramex.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Theramex
Japan Phase III Wins, Asian Alliances Buoy Kissei's Linzagolix
While its European licensee is preparing for an imminent launch, Kissei has also been expanding its partnerships in Asia for female health product linzagolix. A new alliance is also being sought in the US to assist with a new trial and NDA refiling there.
Asia Deal Watch: Chugai Extends Relationship With Helsinn
Plus deals involving Kissei/JWP, Shionogi/Cilcare, Takeda/Torrent, Genome & Co./Debiopharm, Kaken/J&J, CStone/Ewopharma, MediLink/BioNTech and more.
Enzene CEO On Biosimilar Denosumab And Cetuximab; Medicare Negotiation Impact On US Market
CEO of Enzene Biosciences weighs in on the impact of Medicare negotiations in the US on the biosimilars market even as a US filing is planned for a Prolia biosimilar. In the interview, he says Enzene “is not afraid or concerned” over ongoing litigation with Merck KGaA over an Erbitux biosimilar in India, adding that new modalities like ADCs are being “seriously” considered.
TherapeuticsMD Finds New Exit With Mayne Pharma Licensing Pact
After failure to close of a potential $177m buyout by EW Pharma, TherapeuticsMD will resolve its debt by selling its three-product women’s health portfolio to Mayne.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- CVC Capital Partners SICAV-FIS S.A.
- CVC Capital Partners
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice